Financial Ratios

LINCOLN PHARMACEUTICALS LTD.

NSE : LINCOLNBSE : 531633ISIN CODE : INE405C01035Industry : Pharmaceuticals & DrugsHouse : Private
BSE580.051.35 (+0.23 %)
PREV CLOSE ( ) 578.70
OPEN PRICE ( ) 578.70
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 5283
TODAY'S LOW / HIGH ( )567.05 650.00
52 WK LOW / HIGH ( )365.4 754.25
NSE582.102.2 (+0.38 %)
PREV CLOSE( ) 579.90
OPEN PRICE ( ) 572.10
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 582.10 (2)
VOLUME 41688
TODAY'S LOW / HIGH( ) 565.10 589.00
52 WK LOW / HIGH ( )365.25 755.15
Select year
ParticularsMar2023Mar2022Mar2021Mar2020Mar2019
Operational & Financial Ratios
   Earnings Per Share (Rs)36.4034.6331.0824.7823.32
   CEPS(Rs)40.9738.6634.8527.5225.78
   DPS(Rs)1.501.501.501.501.50
   Book NAV/Share(Rs)250.86216.12182.92152.25131.30
   Tax Rate(%)27.4327.7025.6022.6119.79
Margin Ratios
   Core EBITDA Margin(%)16.7419.2319.9115.2616.57
   EBIT Margin(%)19.2419.6119.4916.9717.03
   Pre Tax Margin(%)18.8519.3219.1316.4615.97
   PAT Margin (%)13.6813.9714.2412.7412.81
   Cash Profit Margin (%)15.4015.6015.9614.1414.16
Performance Ratios
   ROA(%)11.9412.7713.6412.5612.98
   ROE(%)15.5917.3518.5617.4819.35
   ROCE(%)21.8224.2925.2121.8121.68
   Asset Turnover(x)0.870.910.960.991.01
   Sales/Fixed Asset(x)2.893.173.503.733.81
   Working Capital/Sales(x)1.811.891.882.433.06
Efficiency Ratios
   Fixed Capital/Sales(x)0.350.320.290.270.26
   Receivable days85.8183.4984.7795.66104.80
   Inventory Days48.9043.8735.1231.4233.07
   Payable days124.53137.63116.0186.9982.47
Valuation Parameters
   PER(x)9.318.987.235.409.12
   PCE(x)8.278.046.454.868.25
   Price/Book(x)1.351.441.230.881.62
   Yield(%)0.440.480.671.120.71
   EV/Net Sales(x)1.271.291.030.691.28
   EV/Core EBITDA(x)5.795.754.713.656.75
   EV/EBIT(x)6.316.235.133.957.28
   EV/CE(x)1.021.040.870.631.20
   M Cap / Sales1.331.321.060.711.20
Growth Ratio
   Net Sales Growth(%)8.1011.6312.456.538.64
   Core EBITDA Growth(%)5.8613.6729.776.8729.25
   EBIT Growth(%)5.2414.2629.076.5230.87
   PAT Growth(%)5.1111.4125.606.2842.37
   EPS Growth(%)5.1111.4125.416.2842.37
Financial Stability Ratios
   Total Debt/Equity(x)0.000.000.000.020.13
   Current Ratio(x)4.073.373.493.302.32
   Quick Ratio(x)3.342.722.992.761.99
   Interest Cover(x)50.5167.1254.9033.2916.13
   Total Debt/Mcap(x)0.000.000.000.020.08

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.